Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
Rhea-AI Summary
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has scheduled its Q3 2025 earnings release for November 6, 2025, after market close.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day, featuring a corporate update and Q&A session. Investors can join via webcast or teleconference using the dial-in numbers 800-715-9871 (US) or 646-307-1963 (international) with access code 9073428. The webcast will be available on the company's investor relations website for approximately one year.
Positive
- None.
Negative
- None.
CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, November 6th.
Management will host a conference call at 5:00 p.m. Eastern Time on November 6th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference by dialing 800-715-9871 (646-307-1963 for international callers) and providing access code: 9073428. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
Investor Inquiries: ICR Healthcare Mike Piccinino, CFA OrganoIR@icrinc.com Press and Media Inquiries: Organogenesis communications@organo.com
FAQ
When will Organogenesis (ORGO) report Q3 2025 earnings?
How can investors access the Organogenesis Q3 2025 earnings call?
Where can I find the replay of Organogenesis Q3 2025 earnings webcast?
What time is the Organogenesis (ORGO) Q3 2025 earnings call?
